TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Intrahepatic Cholangiocarcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Peng Wang, Doctor) · peng_wang@fudan.edu.cn · 8621-64175590
Contact: Principal Investigator (Peng Wang, Doctor)

Study leads

Peng Wang, MD
Principal Investigator
Fudan University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence

Intrahepatic Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Hangzhou, China · Hanzhou, China

Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Fuyang, China · Hefei, China

The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer

Intrahepatic Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE2

Fairfax, United States

A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (Icc)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shanghai, China